Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed

NCT06102759 | Recruiting

• 1 other identifier: TJMUCH-GI-GC04
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib and Adebrelimab combined with paclitaxel/albumin paclitaxel for second-line treatment of advanced gastric cancer.

Conditions

Gastric Cancer

Keywords

gastric cancer; second-line treatment; Adebrelimab; Fruquintinib; chemotherapy

Outcome Measures

Primary Outcomes (1)

• Progression Free Survival

  Time from the start of treatment to the progression of the disease

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months

Secondary Outcomes (3)

• Disease Control rate

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

• The Overall Response Rate

  Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

• Overall survival

  From date of randomization until the date of death from any cause or the last visit date, whichever came first, assessed up to 60 months

Study Arms (1)

Adebrelimab, Fruquintinib combined with paclitaxel

Fruquintinib 4mg d1-14, q3w Paclitaxel 150mg/m2, d1, q3w / Albumin paclitaxel 125mg/m2, d1, d8, q3w PD-L1 antibody (Adebrelimab) 20 mg/kg, d1, q3w

Drug: Adebrelimab，Fruquintinib

Interventions

Adebrelimab，Fruquintinib DRUG

Adebrelimab，Fruquintinib combined with chemotherapy

Adebrelimab, Fruquintinib combined with paclitaxel

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Advanced gastric cancer that failed first-line treatment with PD1 antibody

You may qualify if:

• Age ≥18 years old.
• The ECOG score is 0-1 and does not deteriorate within 7 days.
• Patients with histologically confirmed, metastatic, or unresectable locally advanced gastric cancer or GEJ adenocarcinoma.
• Previously received one systemic chemotherapy regimen for this cancer and progressed; Or have received adjuvant chemotherapy, but have disease progression or recurrence within 6 months after the end of treatment.
• First-line exposure to PD-1 antibodies and first-line treatment of PFS greater than 9 months.
• Measurable lesions that meet RECIST 1.1 criteria.
• Have adequate organ and bone marrow function, laboratory tests meet the following requirements:
• HGB≥90g/L;
• NEUT≥1.5×10\^9/L;
• PLT ≥80×10\^9/L;
• TBIL≤1.5 times upper limit of normal value (ULN);
• ALT and AST≤2.5 x ULN; In liver metastasis, ALT and AST≤5×ULN;
• Endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula);
• Urinary protein \< (++), or 24-hour urinary protein volume \< 1.0 g.
• Normal coagulation function, no active bleeding

You may not qualify if:

• Previous treatment with VEGFR inhibitors;
• Previously received paclitaxel therapy (except for those who received paclitaxel therapy in neoadjuvant or adjuvant therapy, and the treatment ended more than 6 months after the disease progression);
• Receive live vaccine within 4 weeks prior to enrollment or possibly during the study period;
• Had active autoimmune disease or history of autoimmune disease within 4 weeks prior to enrollment;
• Previously received allogeneic bone marrow transplantation or organ transplantation;
• Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥90 mmHg;
• Had any disease or condition affecting drug absorption before enrollment, or the patient could not take drugs orally;
• Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unexcised tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by researchers before enrollment;
• Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months \> 30 mL, hematemesis, stool, stool blood), hemoptysis, or thromboembolic events (including stroke events and/or transient ischemic attacks) within 12 months;
• Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure \> Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) \< 50%;
• Active or uncontrolled severe infection (≥CTCAE v5.0 grade 2 infection);
• Known human immunodeficiency virus (HIV) infection. Known history of clinically significant liver disease, including viral hepatitis \[Known hepatitis B virus (HBV) carriers must rule out active HBV infection, i.e., positive HBV DNA (\>1×104 copies /mL or \> 2000 IU/ mL); known hepatitis C virus infection (HCV) and HCV RNA positive (\>1×103 copies /mL);
• Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, reasonably suspects that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or which would affect the interpretation of the study results or place the patient at high risk;

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead

Study Sites (1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300060, China

RECRUITING

Related Publications (1)

• 1. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, Adaptive, and Acquired Resistance toCancer Immunotherapy. Cell 2017; 168: 707-723. 2. Teng MW, Ngiow SF, Ribas A, et al. Classifying Cancers Based on T-cell Infiltration and PD-L1.Cancer Res 2015; 75: 2139-45. 3. Olson DJ, Eroglu Z, Brockstein B, et al. Pembrolizumab Plus Ipilimumab Following Anti-PD1/L1 Failure in Melanoma. J Clin Oncol 2021; 39: 2647-2655. 4. Pires da Silva I, Ahmed T, Reijers ILM, et al. Ipilimumab alone or ipilimumab plus anti-PD-1therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre,retrospective, cohort study. Lancet Oncol 2021; 22: 836-847. 5. Zaremba A, Eggermont AMM, Robert C, et al. The concepts of rechallenge and retreatmentwith immune checkpoint blockade in melanoma patients. Eur J Cancer 2021; 155: 268-280. 6. Yang K, Li J, Sun Z, et al. Retreatment with immune checkpoint inhibitors in solid tumors: asystematic review. Ther Adv Med Oncol 2020; 12: 1758835920975353. 7. Vera Aguilera J, Paludo J, McWilliams RR, et al. Chemo-immunotherapy combination afterPD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res2020; 30: 364-375. 8. Giaj Levra M, Cotte FE, Corre R, et al. Immunotherapy rechallenge after nivolumabtreatment in advanced non-small cell lung cancer in the real-world setting: A national data baseanalysis. Lung Cancer 2020; 140: 99-106. 9. Kitagawa S, Hakozaki T, Kitadai R, et al. Switching administration of anti-PD-1 and anti-PD-L1antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small celllung cancer: Case series and literature review. Thorac Cancer 2020; 11: 1927-1933. 10. Takahara Y, Tanaka T, Ishige Y, et al. Efficacy and predictors of rechallenge with immunecheckpoint inhibitors in non-small cell lung cancer. Thorac Cancer 2022; 13: 624-630. 11. Zhang Y, Wang ZX, Shen L, et al. A phase Ib/II study of fruquintinib in combination withpaclitaxel as the second-line therapy for advanced gastric cancer. Cancer Commun (Lond) 2023; 43:150-153.

  RESULT

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Ting Deng, MD

  Tianjin Medical University Cancer Institute and Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ting Deng, MD

CONTACT

022-23340123; xymcdengting@126.com

Jiayu Zhang, MD

CONTACT

15201752860; zhangjiayu152@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 22, 2023
• First Posted: October 26, 2023
• Study Start: November 10, 2023
• Primary Completion (Estimated): October 10, 2026
• Study Completion (Estimated): October 10, 2026
• Last Updated: October 26, 2023

Record last verified: 2023-10

Locations

CN (1)